Skip to main content
SpringerLink
Log in

Stellungnahme der Deutschen Gesellschaft für Kardiologie zu den neuen US-Leitlinien zur Verminderung des Atheroskleroserisikos mittels lipidsenkender Therapie

Statement of the Deutsche Gesellschaft für Kardiologie (German Society for Cardiology) on the new US guidelines on reducing atherosclerotic risk using lipid-lowering therapy

  • Leitlinien
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421

    Google Scholar 

  2. Stone NJ, Robinson J, Lichtenstein AH et al (2013) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (Epub ahead of print)

  3. Prevention guidelines tools: CV risk calculator. Dallas: American Heart Association, 2013 (http://my.americanheart.org/cvriskcalculator)

  4. Ridker PM, Cook NR (2013) Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382:1762-1765

    Article  PubMed  Google Scholar 

  5. Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301–1317

    Article  PubMed  CAS  Google Scholar 

  6. Nakamura H, Arakawa K, Itakura H et al (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155–1163

    Article  PubMed  CAS  Google Scholar 

  7. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622

    Article  PubMed  CAS  Google Scholar 

  8. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207

    Article  PubMed  CAS  Google Scholar 

  9. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696

    Article  PubMed  CAS  Google Scholar 

  10. Sever PS, Dahlof B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158

    Article  PubMed  CAS  Google Scholar 

  11. Ridker PM, Wilson PWF (2013) A trial-based approach to statin guidelines. JAMA 310:1123–1124

    Article  PubMed  CAS  Google Scholar 

  12. The European Atherosclerosis Society (EAS) (2013). New guidelines in USA: how do they compare with the EAS/ESC guidelines for the management of dyslipidemia? EAS-Newsletter vom 22.11.2013. http://www.eas-society.org/News.aspx?newsId=316

Download references

Interessenkonflikt

H. Gohlke, W. Koenig, H. Schunkert, N. Marx und C. Hamm geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. -, Neue Kirchstr.22, 79282, Ballrechten-Dottingen, Deutschland

    H. Gohlke FESC, FACC

  2. Klinik für Innere Medizin II, Zentrum für Innere Medizin, Universitätsklinikum Ulm, Ulm, Deutschland

    W. Koenig

  3. Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, München, Deutschland

    H. Schunkert

  4. Medizinische Klinik I, Universitätsklinikum Aachen, Aachen, Deutschland

    N. Marx

  5. Medizinische Klinik I, Kardiologie/Angiologie, Universitätsklinikum Gießen u. Marburg GmbH, Gießen, Deutschland

    C. Hamm

Authors
  1. H. Gohlke FESC, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Koenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Schunkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Marx
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Hamm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Gohlke FESC, FACC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gohlke, H., Koenig, W., Schunkert, H. et al. Stellungnahme der Deutschen Gesellschaft für Kardiologie zu den neuen US-Leitlinien zur Verminderung des Atheroskleroserisikos mittels lipidsenkender Therapie. Kardiologe 8, 120–124 (2014). https://doi.org/10.1007/s12181-014-0555-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-014-0555-2

Search

Navigation